{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:10:56Z","timestamp":1778821856203,"version":"3.51.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy driven by KRAS mutations in ~90% of cases, with high heterogeneity and limited efficacy of single targeted agents. Patient-derived organoids (PDOs) and xenografts (PDXs) offer promising platforms for personalized therapy by replicating tumor characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established a PDAC biobank with 69% PDO and 31% PDX success rates from 66 patient samples. Next-generation sequencing (NGS) of 425 oncogenes was performed, followed by 32-drugs in vitro screening in PDOs. The synergistic effects of the MEK inhibitor trametinib combined with the mTOR inhibitor AZD8055 or the pan-CDK inhibitor flavopiridol were evaluated in PDOs and validated in matched PDXs. We also validated PDOs in predicting clinical gemcitabine\/paclitaxel (Gem\/PTX) responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PDOs preserved tumor histological and genetic feature, with consistent drug responses across early and late passages. Trametini\/AZD8055 exerted robust synergistic antitumor effects in all tested PDO and PDX models, while trametinib\/flavopiridol failed in PDO\/PDX-099. The Gem\/PTX regimen achieved 75 -95% growth inhibition in PDOs, and the in vitro results were highly consistent with the in vivo efficacy in PDXs and the clinical CA19-9 remission of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study effectively integrated two preclinical models, PDOs and PDXs, both in vitro and in vivo, which are highly regarded in the fields of drug discovery and personalized medicine. The trametinib\/AZD8055 combination is a promising precision therapeutic strategy, and PDOs can serve as a reliable tool to guide clinical therapy selection. Despite limitations such as small sample size, lack of tumor microenvironment and immune components in the model system, this work provides important preclinical evidence for the clinical translation of PDOs in the personalized therapy of PDAC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1760379","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:27:34Z","timestamp":1778819254000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK\/mTOR inhibition and predictive chemotherapy responses"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaorui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Endocrinology, Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Da","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine Center, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]},{"name":"Department of Medical Oncology, The First Affiliated Hospital of Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aec7929","article-title":"Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma","volume":"391","author":"Than","year":"2026","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0281-6","article-title":"From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer","volume":"17","author":"Nevala-Plagemann","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1901075116","article-title":"Aldh1b1 expression defines progenitor cells in the adult pancreas and is required for Kras-induced pancreatic cancer","volume":"116","author":"Mameishvili","year":"2019","journal-title":"P Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-020-19058-4","article-title":"Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids","volume":"11","author":"Schuster","year":"2020","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1398","article-title":"Identification of resistance pathways specific to Malignancy using organoid models of pancreatic cancer","volume":"25","author":"Ponz-Sarvise","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3973","article-title":"Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids","volume":"21","author":"Huang","year":"2015","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-1522","article-title":"Oral mucosal organoids as a potential platform for personalized cancer therapy","volume":"9","author":"Driehuis","year":"2019","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-18-0349","article-title":"Organoid profiling identifies common responders to chemotherapy in pancreatic cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov"},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/path.4651","article-title":"Preclinical models of pancreatic ductal adenocarcinoma","volume":"238","author":"Hwang","year":"2016","journal-title":"J Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107764","article-title":"Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers","volume":"31","author":"Ozkan-Dagliyan","year":"2020","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00181","article-title":"What is synergy? The Saariselk\u00e4 agreement revisited","volume":"6","author":"Tang","year":"2015","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12861-020-0209-5","article-title":"Long-term expansion, genomic stability and in vivo safety of adult human pancreas organoids","volume":"20","author":"Georgakopoulos","year":"2020","journal-title":"BMC Dev Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.Ccr-14-1591","article-title":"Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer","volume":"21","author":"Alagesan","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0270-2","article-title":"A phase I\/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors","volume":"33","author":"Kasuga","year":"2015","journal-title":"Invest New Drug"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-1854","article-title":"Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer","volume":"75","author":"Pettazzoni","year":"2015","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31603","article-title":"Phase I\/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer","volume":"143","author":"Van Cutsem","year":"2018","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2022.1367","article-title":"Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)-basis and current status","volume":"16","author":"Ramaswamy","year":"2022","journal-title":"Ecancermedicalscienc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2380958","article-title":"Clinical significance of color ultrasound, MRI, miR-21, and CA199 in the diagnosis of pancreatic cancer","volume":"2021","author":"Yu","year":"2021","journal-title":"J Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04165-2","article-title":"The prognostic value of CA19\u20139 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis","volume":"86","author":"Ye","year":"2020","journal-title":"Cancer Chemoth Pharm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:27:36Z","timestamp":1778819256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1760379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1760379"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1760379","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1760379"}}